Skip to main content
. 2015 Jun 15;5:11348. doi: 10.1038/srep11348

Figure 3. The results of meta-analysis of association between BIM deletion polymorphism and progression-free, overall survival in malignancy with kinase inhibitor therapy.

Figure 3

(A) BIM deletion polymorphism and progression-free survival; (B) BIM deletion polymorphism and overall survival.